Roberts Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Roberts Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-250	Closed	-$263K	–	86
2024 Q3	$263K	Hold	250	–	–	0.22%	83
2024 Q2	$241K	Hold	250	–	–	0.23%	84
2024 Q1	$241K	Buy	+250	New	+$238K	0.23%	84
2022 Q3	$185K	Hold	268	–	–	0.27%	84
2022 Q2	$158K	Hold	268	–	–	0.22%	86
2022 Q1	$187K	Hold	268	–	–	0.19%	93
2021 Q4	$169K	Buy	+268	New	+$165K	0.16%	93

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Roberts Capital Advisors's REGN Position: Q4 2024 in Review

Roberts Capital Advisors sold out of Regeneron Pharmaceuticals (REGN) in Q4 2024, closing a stake of 250 shares — an estimated $263K sold.

Roberts Capital Advisors first reported a position in REGN in Q4 2021 and held it in 7 quarters. The position peaked at $263K in Q3 2024. 1,318 funds tracked by Wall St. Rank hold REGN as of Q4 2024.

Roberts Capital Advisors reported no remaining Regeneron Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Roberts Capital Advisors sold 250 Regeneron Pharmaceuticals shares in Q4 2024, an estimated $263K.
Roberts Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q4 2021 and held it in 7 quarters.
Roberts Capital Advisors's Regeneron Pharmaceuticals position peaked at $263K in Q3 2024.
1,318 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2024.

Based on Roberts Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.